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Abstract
The availability of diverse RT-qPCR assay formats and technologies hinder comparability of data between platforms.
Reference standards to facilitate platform evaluation and comparability are needed. We have explored using
universal RNA standards for comparing the performance of a novel qPCR platform (Fluidigm
® BioMark™) against
the widely used ABI 7900HT system. Our results show that such standards may form part of a toolkit to evaluate
the key performance characteristics of platforms.
Background
Reverse transcription quantitative PCR (RT-qPCR) is
rapidly becoming a valuable tool for mRNA biomarker
quantification in clinical diagnostics. There has been a
proliferation of RT-qPCR assay formats and platforms in
recent years due to wider applications of this technol-
ogy, coupled with improvements in sensitivity, specificity
and accuracy of measurements of gene expression. How-
ever, there is one intrinsic limitation to the current
qPCR platforms, namely lack of controls for cross-
platform comparison. Although the manufacturers have
developed platform-specific quality controls, they are
often not adequate for cross-platform comparisons, par-
ticularly for the evaluation and standardization of tran-
scriptomic data due to differences in protocols, data
processing and analysis methods. Thus, development of
universal RNA standards offers great potential in the
validation of data obtained from different RT-qPCR
methods. In the present investigation, we have com-
pared the performance of Fluidigm
® BioMark™ Inte-
grated microfluidic (henceforth referred to as BioMark)
dynamic arrays with the widely used ABI 7900HT real-
time PCR platform (henceforth called ABI 7900HT sys-
tem) using generic RNA standards.
Pre-amplification of RNA or cDNA facilitates the inves-
tigation of a large number of genes when the starting
material is limiting, such as with tissue biopsies and archi-
val formalin-fixed paraffin-embedded (FFPE) samples
[1,2]. Pre-amplification methods used generally include
either linear amplification of RNA or exponential (PCR-
based) amplification of cDNA [3-5]. However, concerns
have been raised as to whether pre-amplification of sam-
ples by exponential amplification introduces bias in
expression levels between genes [6]. For the BioMark
microfluidic PCR system, each sample in the 48 × 48
dynamic array is distributed amongst 48 different reaction
chambers, therefore pre-amplification is recommended for
certain applications. However the limit of detection (LOD)
of using pre-amplified vs. non-amplified cDNA samples,
and its impact on the technical performance of the PCR
array have not been fully characterized.
Exogenous RNA controls produced by in vitro tran-
scription are ideal materials for investigating different
RT-qPCR kits and methodologies [7]. Recently a panel
of RNA controls have been developed for use in gene
expression applications by the External RNA Controls
Consortium (ERCC), an ad hoc group of 70 members
from private, public and academic organizations led by
the National Institute of Standards (NIST) [8,9]. It is
hoped that standards developed from these sequences
will aid in comparisons of gene expression data gener-
ated from various platforms such as microarray, RT-
qPCR and next generation sequencing, and also provide
quality control of gene expression measurements in the
clinical laboratory [10]. Multigene biomarker measure-
ments are at the forefront of a new class of medical
devices using in vitro diagnostic multivariate assays,
such as MammaPrint and Oncotype Dx in the area of
breast cancer prognosis [11]. Since gene expression bio-
markers typically encompass a range of transcript abun-
dances and differential expression ratios, it is more
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controls for standardizing such measurements, as
opposed to a single transcript at a fixed concentration.
In the current study, we used a sub-set of the 96
ERCC RNA standards (Additional File 1) in order to
characterize their performance on a nanofluidic PCR
system, the BioMark 48 × 48 dynamic arrays, against a
conventional qPCR platform, the ABI 7900HT system.
We also investigated the impact of pre-amplification of
cDNA samples on the linear range and precision of
measurements by nanofluidic qPCR. Two prototype
panels were constructed with selected RNA standards
containing varying copy number within each panel, and
varying ratios between them for mimicking non-differ-
entially and differentially expressed mRNA biomarkers
as represented in normal and disease states. The expres-
sion profile of the RNA standards was measured using
both platforms and the accuracy and precision of their
detection were compared.
Results
Linear range of dynamic arrays
One advantage of the BioMark arrays is the capability to
analyse a large number of genes in a single sample. In
order to facilitate this, up to ~ 2 μL of sample is loaded
into each sample inlet of the chip and further distribu-
ted in the channels of the microfluidic chip as 48 sepa-
rate 9 nL reactions using the integrated fluidic circuit
(IFC). Thus the original sample is diluted more than
200-fold prior to the PCR reaction. In order to ensure
that there are sufficient copies of target molecules in
each reaction, Fluidigm
® recommends using either RNA
samples that do not have a concentration lower than
250 ng total RNA/μL or that a pre-amplification stage is
included, whereby the cDNA sample undergoes 14-18
cycles of amplification with a mix of up to 100 different
primer pairs (Fluidigm Advanced Development Proto-
cols 3, 5 and 8). In order to further investigate the
requirement for pre-amplification, RNA standards were
spiked into human total RNA at different concentrations
(for sample composition, see Additional File 2) with the
aim of mimicking a range of physiological abundances,
from highly abundant mRNA transcripts (10
6 copies/ng
total RNA; equivalent to 10
4 copies per cell) to tran-
scripts only expressed in a sub-population of cells (1
copy/ng total RNA; equivalent to 0.01 copies per cell),
based on the RNA content of a cell estimated as 26 pg
[12]. A single RT reaction was performed for each RNA
sample followed by 3 independent qPCR runs, with
replicate assay measurements for each ERCC standard.
Figure 1 compares the results of real-time PCR with
cDNA samples (equivalent to 1 ng total RNA) or pre-
amplified cDNA on the BioMark arrays with non-amplified
cDNA using the ABI 7900HT system. The linear range in
terms of transcript copy numbers for the pre-amplified
cDNA samples on the BioMark arrays was similar to the
non-amplified cDNA samples on the ABI 7900HT system,
covering five orders of magnitude between 10 and 10
6
copies/ng total RNA. Although the linear range of both
platforms was similar, the Ct values from BioMark were
over 10 units lower than those observed for ABI 7900HT
system. This could be due to the higher concentration of
the template in the 9 nL nanofluidic reaction chambers of
BioMark arrays compared to the standard 20 μLv o l u m e
used on the ABI 7900HT system, such that the fluores-
cence output of the PCR reaction exceeds the threshold
level at an earlier cycle (personal communication: A.
Meliss, Fluidigm, September 2009). For the RT-PCRs per-
formed with non-amplified cDNA samples on BioMark
arrays, the linear detection range covered only two orders
of magnitude between the transcript numbers of 10
4 and
10
6 copies/ng.
LOD of dynamic arrays
Unlike hybridization-based technologies such as micro-
arrays, the LOD cannot be ascribed for RT-qPCR using
a baseline for sample blanks, as a Ct value is not
obtained for zero control samples. Therefore, the inci-
dence of failed PCR reactions (undetermined Ct value)
across the range of transcript abundances was also com-
pared for conventional and nanofluidic PCR platforms
with pre- or non-amplified cDNA as the template
( F i g u r e2 ) .A si nF i g u r e1 ,ah i g hp e r c e n t a g eo fP C R
failures was observed at 1 copy/ng total RNA for both
pre-amplified cDNA on the BioMark arrays and cDNA
using the ABI 7900HT system. The rate of failures was
slightly lower on the BioMark arrays as the projected
template concentration per 9 nL reaction was 6 copies
(assuming 100% efficiency of RT and pre-amplification),
whilst it was only 1 RNA copy per ABI 7900HT reac-
tion. For non-amplified cDNA, high reaction failure
rates with BioMark arrays were observed below 10
3
copies/ng, which equates to 2 copies per 9 nL reaction.
qPCR accuracy and precision
The accuracy and precision of qPCR detection across the
above noted linear range was assessed by linear regres-
sion, comparing the slope and R
2 of the data from three
independent dynamic arrays (Table 1). Pre-amplification
of cDNA samples resulted in a significant improvement
in the slope of the linear regression of copy number
a g a i n s tC tv a l u e( p <0 . 0 5 ) ,w i t ht h em e a ns l o p ew i t h i n
6% of the ideal slope of 1. The pre-amplified cDNA sam-
ples demonstrated greater precision of the instrument
over the linear detection range (Figure 1) than cDNA
(p < 0.05) (Table 1). The accuracy and precision of
pre-amplified cDNA detection on the BioMark arrays
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non-amplified cDNA was used as the template (Table 1).
Precision of qPCR detection as a function of transcript
copy number for the two platforms is shown in Figure 3.
For concentrations of RNA standards above 10
4 copies/
ng (using cDNA with the ABI 7900HT system or pre-
amplified cDNA for the BioMark arrays), and above 10
6
copies/ng (with non-amplified cDNA for the BioMark
arrays), Ct standard deviation values are below 0.1 units,
corresponding to less than 7% variation [13]. As RNA
Figure 1 Linear range of RT-qPCR platforms. Example plot showing detection of an ERCC RNA standard (ERCC-42) across a range of transcript
copy numbers from 1 to 10
6 copies per ng total RNA with cDNA (triangles) or pre-amplified cDNA (diamonds) as the template on (A) BioMark
(B) ABI 7900HT system. Data-points are displayed as individual qPCR replicates. Dotted line indicates linear detection range.
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qPCR measurements increases, with maximum average
standard deviation values corresponding to 46% and 66%
variation at 10 copies/ng for the BioMark arrays (pre-
amplified cDNA) and ABI 7900HT system respectively
(Figure 3).
RNA biomarker panels
The accuracy of nanofluidic dynamic PCR for detection
of multiple genetic biomarkers was further tested using
two panels of RNA standards. With the aim of mimick-
ing ‘normal’ and ‘disease’ states where some biomarkers
are differentially expressed whilst others remain
Figure 2 Limit of detection of ERCC RNA standards. Incidence of failed PCR reactions on ABI 7900HT system or BioMark using cDNA or pre-
amplified cDNA as the template. Mean percentage of failed PCR reactions ± SD are displayed based on data from 8 different RNA standards
from 3 independent qPCR experiments across a range from 1 to 10
6 copies ERCC standard per ng total RNA.
Table 1 Accuracy and precision of linear detection range of PCR platforms
Slope R
2
Platform Dynamic arrays ABI 7900HT Dynamic arrays ABI 7900HT
Template Pre-amplified
cDNA
cDNA cDNA Pre-amplified
cDNA
cDNA cDNA
ERCC-
13 -1.06 -1.08 -1.06 0.999 0.993 0.997
42 -1.07 -1.11 -1.06 0.998 0.970 0.995
81 -1.02 -1.07 -1.04 0.998 0.976 0.998
84 -1.03 -1.07 -1.01 0.998 0.973 0.996
95 -1.07 -1.12 -1.08 0.997 0.975 0.998
99 -1.06 -1.06 -1.05 0.998 0.985 0.997
113 -1.06 -1.15 -1.04 0.998 0.971 0.997
171 -1.12 -1.13 -1.08 0.998 0.982 0.996
All -1.06 -1.10 -1.05 0.999 0.978 0.997
Linear regression was performed with Ct values vs. log2(ERCC RNA copy number) for each PCR platform across the linear range marked in Figure 1. The mean slope and
R
2 values from three independent qPCR experiments reflect the accuracy and precision of the detection of the 10-fold differences in copy numbers between samples.
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Page 4 of 10unchanged in their expression, standards were spiked at
different ratios (1.0, 1.5, 2.0, 5.0, 10.0 and 20-fold differ-
ences) over a range of transcript copy numbers (Table 2).
Three independent RT experiments, each containing two
replicate RT reactions, were performed in order to inves-
tigate how technical noise associated with the whole RT-
qPCR process impacts on the detection of differential or
non-differential transcript expression levels. The result-
ing cDNA was quantified on the ABI 7900HT system or
pre-amplified and measured on the BioMark. Fold
change values were calculated using ΔCt values and the
results of pair-wise comparison of the expression levels
of each ERCC standard in the two panels displayed in
Figure 4.
Overall, fold change estimation was found to be accu-
rate for both ABI 7900HT system and BioMark arrays
(Figures 4A and 4B), with the observed fold change
values overlapping with the expected fold change mea-
surements for all standards. For ERCC standards
mimicking low abundance transcripts, the technical noise
associated with the resulting fold change measurement
was considerably greater than higher abundance RNA
species. For example, a 20-fold increase in expression
level at 5 copies/ng (ERCC-51) is associated with 16-fold
and 10-fold difference in the minimum and maximum
fold changes detected by the BioMark arrays and ABI
7900HT system respectively. For non-differential expres-
sion at low copy numbers (fold change = 1.0; ERCC-113),
fold change measurements spanned a range of over 50%
and 150% of the expected value on the BioMark and ABI
7900HT system respectively. At levels of abundance
exceeding 100 copies/ng, mean fold change measure-
ments were accurate to within 10% of expected values.
Figure 3 Precision of real-time PCR platforms. Within-run qPCR precision across a range of transcript abundance levels (copies per ng total
RNA) are displayed for cDNA or pre-amplified cDNA quantified using ABI 7900HT system or BioMark. Mean variation (SD) of Ct values ± SD is
displayed based on data from eight different RNA standards from three independent qPCR experiments.
Table 2 Concentrations and ratios of ERCC RNA
standards in simulated ‘normal’ and ‘disease’ panels
ERCC standard Copies/ng total RNA Ratio B/A
Panel A Panel B
13 1 × 10
5 1×1 0
5 1.0
25 1 × 10
2 1.5 × 10
2 1.5
42 1 × 10
4 5×1 0
3 0.5
51 5 × 10
0 1×1 0
2 20.0
81 1 × 10
2 1×1 0
2 1.0
84 1 × 10
2 5×1 0
2 5.0
95 1 × 10
3 1×1 0
3 1.0
99 8 × 10
3 1.2 × 10
4 1.5
113 1 × 10
1 1×1 0
1 1.0
171 1 × 10
1 1×1 0
2 10.0
10 ERCC RNA standards were spiked in a background of Universal Human
Reference RNA at different concentrations and ratios in order to create
simulated ‘normal’ and ‘disease’ panels, A and B.
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Page 5 of 10Figure 4 Accuracy of fold change detection. Two panels (A and B) containing different ratios of RNA standards across a range of copy
numbers were quantified using (A) cDNA with the ABI 7900HT system or (B) pre-amplified cDNA with BioMark 48 × 48 dynamic arrays. Expected
fold change values (see the tables below the Figures) are compared to the mean of measured fold changes from RT-qPCR reactions performed
on six pairs of samples. The error bars represent standard error.
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In this study we sought to demonstrate the utility of
RNA standards for characterisation of a new platform,
the BioMark, where PCR reactions are performed in
volumes over a 1000-fold lower than on a conventional
RT-qPCR instrument (ABI 7900HT system). The
requirement for sample pre-amplification for this tech-
nology contrasts with standard two-step RT-qPCR
approach, therefore the impact of this methodology was
also evaluated. Dilutions of RNA standards across a
wide physiological range demonstrated that the linear
detection range of the BioMark arrays is similar to the
ABI 7900HT real-time PCR system, when pre-amplified
cDNA is used as the template (Figure 1). The precision
of replicate measurements within the array also com-
pared favourably to the intra-run standard deviation of
Ct values for the ABI 7900HT system (Figure 3). At
copy numbers mimicking medium to high abundance
transcripts, the precision of the BioMark arrays is in a
similar range to the minimum variation of ~ 0.1 units
observed for another nanofluidic PCR array, the Open-
Array format [14].
However, when non-amplified cDNA is quantified
using the nanofluidic BioMark arrays, the linear range
is severely limited, to only two orders of magnitude
(Figure 1). At the lower detection limit of 10
4 RNA
copies per reaction (Ct ~ 27), the variation between
measurements increases significantly (Figure 3), whilst
below this level of abundance, the rate of PCR failures
increases rapidly (Figure 2). Pre-amplification of tem-
plate cDNA using a preliminary PCR step of 14 cycles
improves both the accuracy and precision of the tran-
script quantification using the dynamic arrays (Table 1).
The improved detection of the 10-fold differences in
RNA copy numbers between sample series (resulting in
an average slope within 6% of expected value) also indi-
cates that the pre-amplification process does not intro-
duce bias into the detection of transcripts which cover a
wide dynamic range.
Relative expression measurements are central to gene
expression analysis by RT-qPCR and for determining
whether a panel of biomarkers has predictive power for
disease diagnosis and prognosis [15]. Therefore, we
developed two panels of RNA standards in order to
further investigate the accuracy of detecting gene expres-
sion ratios using the new type of PCR array compared to
an established system. The standards were spiked at vary-
ing ratios between panels in order to obtain information
on how well the methodologies can discriminate between
differentially and non-differentially expressed candidate
genes at different transcript abundance levels (Figure 4).
Our results show good accuracy of observed vs. expected
values for both platforms, which is in agreement with
previous studies demonstrating good concordance of fold
change measurements between the BioMark arrays and
the ABI 7900HT system [16]. The precision of the fold
change estimation varied according to the abundance of
the transcripts, demonstrating increased variation in the
observed values for lower concentrations of standards for
both nanofluidic and standard real-time PCR approaches.
This suggests that the sensitivity of the technique to cor-
rectly detect the expected fold change is reduced at low
copy numbers (10 RNA copies or less per reaction on the
ABI 7900HT system). Dixon et al. [14] also found that
the sensitivity of the OpenArray platform was lower for
Ct values corresponding to lower copy numbers, result-
ing in an increased number of false negative results. The
increased variation in fold change detection at low copy
numbers is likely to arise due to decreased efficiency at
RT stage and increased stochastic variation in the PCR
reaction for low target numbers [17].
We also found that both qPCR platforms were able to
accurately detect a 1.5-fold change in mRNA expression,
below the 2-fold cut-off which has been cited as a limit
to the resolving power of conventional PCR, as it consti-
tutes a difference of less than a single cycle [18]. The
BioMark dynamic arrays were recently shown to be able
to detect a 1.25-fold difference in DNA copy number by
qPCR, with greater levels of precision achievable with
the larger number of technical replicates possible with
this high-throughput approach [19]. Since assay and
sample loadings are in separate inlets on 48 × 48
dynamic arrays, it is possible to increase technical repli-
cation by using multiple assay inlets and/or multiple
sample inlets. However, it should be noted that replica-
t i o no n l ya tt h ea s s a yl e v e ld o e sn o ts u b s t i t u t ef o rt r u e
sampling variation by the process of taking a sample
from a population of molecules.
The use of gene-specific oligonucleotide standards for
inter-run and cross-platform calibration has been
demonstrated to improve the accuracy of class predic-
tion based on panels of biomarkers [15]. Although
ERCC RNA standards do not directly provide informa-
tion on the performance of biomarker-specific assays, a
panel of multiple standards, such as that used here pro-
vides a robust means of evaluating platform perfor-
mance by minimizing confounding effects resulting
from differences in assay performance due to individual
primer and probe specificity. RNA standards could also
serve as calibrator samples between experiments where
different sets of potential biomarkers genes are investi-
gated, as well as in the context of a diagnostic assay
where the expression of the same panel of genes is
quantified. In addition to target gene normalization
using a reference gene or panel of reference genes [20],
normalization to an ERCC RNA standard or multiple
RNA standards may be a useful control for elucidating
technical variation due to RT and qPCR steps [21].
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We conclude that universal RNA standards can provide
robust information on the performance characteristics
of different RT-qPCR platforms and methodologies. The
results obtained using panels of multiple RNA standards
indicate that the linear detection range, precision and
accuracy of nanofluidic BioMark dynamic arrays are
similar to those of an established real-time PCR instru-
ment, the ABI 7900HT system, when pre-amplified
cDNA is used as the template. The standards also
provide reference values for the range of transcript
a b u n d a n c eo v e rw h i c hi tw o u l db ep o s s i b l et om e a s u r e
non-amplified cDNA on the nanofluidic BioMark high-
throughput arrays. Carefully constructed panels of
ERCC RNA standards have the potential to act as
benchmarks for the calibration and interpretation of
biomarker measurements in drug discovery and clinical
diagnostics. Further evaluation of these standards is
required for potential incorporation into a ‘quality
metrics’ toolkit for assessing their suitability for cross-
platform comparisons.
Methods
Preparation of in vitro transcribed RNA and samples
In vitro transcribed ERCC RNA standards were produced
from ERCC plasmid DNA (courtesy of Dr. Marc Salit,
NIST, USA). Plasmid DNA from standards ERCC-13, 25,
42, 51, 81, 84, 95, 99, 113 and 171 was cleaved into a single
linear molecule using BamHI restriction endonuclease
(New England Biolabs, UK). 500 ng of plasmid DNA was
used for each sample and digested by adding 40 U of
BamHI enzyme in NEB3 buffer provided by the manufac-
turer. The digestion mixture was incubated at 37°C for
2 hours followed by purification using QiaQuick PCR pur-
ification kit with an elution volume of 32 μl. In vitro tran-
scription was carried out with 8 μl digested plasmid DNA
using MEGAscript
® T7 Kit (Applied Biosystems/Ambion,
U K )f o l l o w e db yD N ase treatment and clean-up using
RNeasy columns (Qiagen, UK). RNA concentration and
insert sizes were estimated using the Nanodrop 1000 spec-
trophotometer (Thermo Scientific, UK) and 2100 Bioana-
lyzer (Agilent Technologies, USA) respectively. RNA
standards were diluted in nuclease free-water and spiked
into Universal Human Reference RNA (Stratagene, UK)
(final concentration 100 ng/μl). For experiments investi-
gating the linear range of platform detection, standards
were spiked at 10-fold intervals between 1 and 10
6 copies/
ng total RNA (Additional File 2). For the simulated ‘nor-
mal’ and ‘disease’ panels, standards were spiked at various
copy numbers and ratios (Table 2).
Reverse transcription and pre-amplification of cDNA
RNA samples were reverse-transcribed using the Taq-
Man
® Reverse Transcription Reagents kit (Applied
Biosystems, UK) in 40 μL reactions containing 400 ng
total RNA and oligo(dT) primers according to manufac-
turer’s instructions. cDNA samples were diluted to a con-
centration of 0.5 ng/μL (total RNA equivalent) with
nuclease-free water. For experiments investigating the
linear range of platform detection (Figures 1, 2, 3), a sin-
gle RT reaction was performed for each RNA sample
whilst for the simulated ‘normal’ and ‘disease’ panels
(Figure 4), 6 replicate RT reactions were performed. A sin-
gle aliquot of each cDNA sample, equivalent to 12.5 ng
RNA, was pre-amplified with assays corresponding to all
10 standards in a 25 μL volume reaction using TaqMan
®
PreAmp Mastermix (Applied Biosystems, UK) according
to manufacturer’s protocol. Following pre-amplification,
the samples were diluted 1:5 (v/v) in TE buffer, pH 8.0.
Real-time PCR
Further information on sample preparation and real-
time PCR validation complying with the Minimum
Information for Publication of Quantitative Real-Time
PCR Experiments (MIQE) guidelines [22] is available in
Additional Files 2 and 3 (MIQE Additional Information
and Checklist).
Custom-designed primers and TaqMan
® FAM-
TAMRA probes for each ERCC standard (Additional
File 1) were supplied by Applied Biosystems and a 20 ×
assay mix was prepared containing 18 μMp r i m e ra n d
5 μM probe (final concentration 900 nM primer and
250 nM probe). qPCR assays were tested initially using
a serial dilution of ERCC cDNA and PCR efficiencies
calculated (see Additional Data Table 2: MIQE Addi-
tional information). All 10 assays were found to have
PCR efficiencies of greater than 86%.
BioMark arrays were prepared according to the manu-
facturer’s instructions. TaqMan
® assays were diluted 1:1
(v/v) with DA Assay Loading Reagent (Fluidigm
®)a n d
5 μL was added to each assay inlet of the array. Also,
5 μL reaction mix was prepared by mixing 2 ×
TaqMan
® Universal Mastermix (Applied Biosystems),
DA Sample Loading Reagent and nuclease-free water
containing 2 μL of cDNA or pre-amplified cDNA. The
samples were loaded into each sample inlet as per man-
ufacturer’s recommendations. Following loading of the
assays and samples into the chip by the IFC controller,
PCR was performed with the following reactions condi-
tions: 50°C for 2 minutes, 95°C for 10 minutes, followed
by 45 cycles of 95°C for 15 seconds and 60°C for 60 sec-
onds. Data was processed by automatic global threshold
setting with the same threshold value for all assays and
linear baseline correction using BioMark Real-time PCR
Analysis software (version 2.1.1). The quality threshold
was set at the default setting of 0.65. For experiments
investigating the linear range of platform detection
(Figures 1, 2, 3), 8 qPCR reactions consisting of 4 assay
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each cDNA or pre-amplified cDNA sample. For the
simulated ‘normal’ and ‘disease’ panels (Figure 4),
12 qPCR reactions consisting of 4 assay inlet and 3 sample
inlet replicates were performed for each cDNA sample.
Conventional real-time PCR was performed using ABI
7900HT system in 20 μL reaction volumes containing
TaqMan
® Universal PCR Master Mix and 2 μLo f
respective cDNA in optical 96-well plates (Applied Bio-
systems). Cycling conditions were as those used for the
BioMark arrays. Triplicate qPCR reactions were per-
formed for each cDNA sample for all experiments. The
threshold fluorescence level was set manually for each
plate using SDS software version 2.3 (Applied Biosys-
tems). Following export of Cycle threshold (Ct) data,
further data analysis for both platforms was performed
in Microsoft
® Excel 2003. Comparison of slope and R
2
values between pre-amplified and non-amplified cDNA,
as a template on the BioMark arrays, was performed as
paired t-test in Microsoft
® Excel 2003.
Additional files
The following additional are available with the online
version of this paper. Additional data file 1 is a table
detailing the primer and probe sequences used for
qPCR assays. Additional files 2 and 3 are additional data
and a checklist in compliance with the MIQE (Mini-
mum Information for Publication of Quantitative Real-
Time PCR Experiments) guidelines.
Additional material
Additional file 1: Taqman assays for ERCC RNA standards. Microsoft
Word file detailing the sequences of primers and probes used for qPCR
assays.
Additional file 2: MIQE Additional Information. Microsoft Excel file
containing further information on RNA preparation, purity, PCR efficiency
and negative control data complying with the MIQE guidelines.
Additional file 3: MIQE Checklist. Checklist in Microsoft Word format
detailing information complying with MIQE guidelines.
List of abbreviations
ERCC: External RNA Controls Consortium; RT-qPCR: Reverse Transcription
Quantitative PCR; LOD: limit of detection; FFPE: formalin-fixed paraffin-
embedded; IFC: integrated fluidic circuit; RT: Reverse Transcription; PCR:
polymerase chain reaction.
Acknowledgements
The work described in this paper was funded by the UK National
Measurement System. We are grateful to Dr. Marc Salit (NIST, USA) for the
provision of ERCC plasmid DNA. We would also like to thank Jesus Minguez
(LGC) for statistical analysis and Dr. Bridget Fox (LGC) for assistance with the
production of in vitro transcribed RNA standards.
Authors’ contributions
AD performed RT-qPCR experiments, participated in the design of the study,
performed data analysis and drafted the manuscript. RE participated in the
design of the study and helped to draft the manuscript. CF conceived of
the study, and participated in its design and coordination and helped to
draft the manuscript. All authors read and approved the final manuscript.
Received: 13 October 2010 Accepted: 18 February 2011
Published: 18 February 2011
References
1. Vermeulen J, Derveaux S, Lefever S, De Smet E, De Preter K, Yigit N, De
Paepe A, Pattyn F, Speleman F, Vandesompele J: RNA pre-amplification
enables large-scale RT-qPCR gene-expression studies on limiting sample
amounts. BMC Res Notes 2009, 2:235.
2. Li J, Smyth P, Cahill S, Denning K, Flavin R, Aherne S, Pirotta M, Guenther SM,
O’Leary JJ, Sheils O: Improved RNA quality and TaqMan Pre-amplification
method (PreAmp) to enhance expression analysis from formalin fixed
paraffin embedded (FFPE) materials. BMC Biotechnol 2008, 8:10.
3. Eberwine J, Yeh H, Miyashiro K, Cao Y, Nair S, Finnell R, Zettel M,
Coleman P: Analysis of gene expression in single live neurons. Proc Natl
Acad Sci USA 1992, 89:3010-3014.
4. Kurn N, Chen P, Heath JD, Kopf-Sill A, Stephens KM, Wang S: Novel
isothermal, linear nucleic acid amplification systems for highly
multiplexed applications. Clin Chem 2005, 51:1973-1981.
5. Iscove NN, Barbara M, Gu M, Gibson M, Modi C, Winegarden N:
Representation is faithfully preserved in global cDNA amplified
exponentially from sub-picogram quantities of mRNA. Nat Biotechnol
2002, 20:940-943.
6. Ginsberg SD: RNA amplification strategies for small sample populations.
Methods 2005, 37:229-237.
7. Levesque-Sergerie JP, Duquette M, Thibault C, Delbecchi L, Bissonnette N:
Detection limits of several commercial reverse transcriptase enzymes:
impact on the low- and high-abundance transcript levels assessed by
quantitative RT-PCR. BMC Mol Biol 2007, 8:93.
8. External RNA Controls Consortium: Proposed methods for testing and
selecting the ERCC external RNA controls. BMC Genomics 2005, 6:150.
9. Baker SC, Bauer SR, Beyer RP, Brenton JD, Bromley B, Burrill J, Causton H,
Conley MP, Elespuru R, Fero M, Foy C, Fuscoe J, Gao X, Gerhold DL, Gilles P,
Goodsaid F, Guo X, Hackett J, Hockett RD, Ikonomi P, Irizarry RA,
Kawasaki ES, Kaysser-Kranich T, Kerr K, Kiser G, Koch WH, Lee KY, Liu C,
Liu ZL, Lucas A, et al: The External RNA Controls Consortium: a progress
report. Nat Methods 2005, 2:731-734.
10. Cronin M, Ghosh K, Sistare F, Quackenbush J, Vilker V, O’Connell C:
Universal RNA Reference Materials for Gene Expression. Clin Chem 2004,
50:1464-1471.
11. Ross JS: Multigene classifiers, prognostic factors, and predictors of breast
cancer clinical outcome. Adv Anat Pathol 2009, 16:204-215.
12. Clinical and Laboratory Standards Institute: Use of External RNA Controls
in Gene Expression Assays. 2010, Approved Guideline 26 No. 29, MM16-A.
13. Stahlberg A, Hakansson J, Xian X, Semb H, Kubista M: Properties of the
reverse transcription reaction in mRNA quantification. Clin Chem 2004,
50:509-15.
14. Dixon JM, Lubomirski M, Amaratunga D, Morrison TB, Brenan CJ, Ilyin SE:
Nanoliter high-throughput RT-qPCR: a statistical analysis and
assessment. Biotechniques 2009, 46:ii-viii.
15. Vermeulen J, Pattyn F, De Preter K, Vercruysse L, Derveaux S, Mestdagh P,
Lefever S, Hellemans J, Speleman F, Vandesompele J: External
oligonucleotide standards enable cross laboratory comparison and
exchange of real-time quantitative PCR data. Nucleic Acids Res 2009, 37:
e138.
16. Spurgeon SL, Jones RC, Ramakrishnan R: High throughput gene
expression measurement with real time PCR in a microfluidic dynamic
array. PLoS One 2008, 3:e1662.
17. Bustin SA, Nolan T: Pitfalls of quantitative real-time reverse-transcription
polymerase chain reaction. J Biomol Tech 2004, 15:155-166.
18. Lo YM, Lun FM, Chan KC, Tsui NB, Chong KC, Lau TK, Leung TY, Zee BC,
Cantor CR, Chiu RW: Digital PCR for the molecular detection of fetal
chromosomal aneuploidy. Proc Natl Acad Sci USA 2007, 104:13116-13121.
19. Weaver S, Dube S, Mir A, Qin J, Sun G, Ramakrishnan R, Jones RC, Livak KJ:
Taking qPCR to a higher level: Analysis of CNV reveals the power of
high throughput qPCR to enhance quantitative resolution. Methods 2010,
50:271-6.
20. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A,
Speleman F: Accurate normalization of real-time quantitative RT-PCR
Devonshire et al. BMC Genomics 2011, 12:118
http://www.biomedcentral.com/1471-2164/12/118
Page 9 of 10data by geometric averaging of multiple internal control genes. Genome
Biol 2002, 3:RESEARCH0034.
21. Gilsbach R, Kouta M, Bonisch H, Bruss M: Comparison of in vitro and in
vivo reference genes for internal standardization of real-time PCR data.
Biotechniques 2006, 40:173-177.
22. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, Mueller R,
Nolan T, Pfaffl MW, Shipley GL, Vandesompele J, Wittwer CT: The MIQE
Guidelines: Minimum Information for Publication of Quantitative Real-
Time PCR Experiments. Clin Chem 2009, 55:611-622.
doi:10.1186/1471-2164-12-118
Cite this article as: Devonshire et al.: Applicability of RNA standards for
evaluating RT-qPCR assays and platforms. BMC Genomics 2011 12:118.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Devonshire et al. BMC Genomics 2011, 12:118
http://www.biomedcentral.com/1471-2164/12/118
Page 10 of 10